Lung Cancer, Non-Small Cell Clinical Trials

88 clinical trials for Lung Cancer, Non-Small Cell across international registries, including 19 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC — RECRUITING · PHASE2
• TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO — RECRUITING
• Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device — RECRUITING
• Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques — RECRUITING
• The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer — RECRUITING · NA
• Engagement of Veterans With Lung Cancer — RECRUITING · NA
• Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE1
• A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs — RECRUITING · PHASE1
• Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer — RECRUITING
• Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer — RECRUITING · PHASE2
• Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer — RECRUITING
• Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3) — RECRUITING · PHASE2
• Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer — RECRUITING
• Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients — RECRUITING
• Standard Care With or Without Early Palliative Care Provided by Palliative Care Specialist in Advanced Non-small Cell Lung Cancer Patients — RECRUITING · NA
• A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC — RECRUITING · PHASE2
• Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) — RECRUITING
• Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions — RECRUITING
• TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer — RECRUITING · PHASE1
• A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non Small Cell Lung Cancer — TERMINATED · PHASE2
• A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) — ACTIVE_NOT_RECRUITING · PHASE3
• A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARLIMAB + DOCETAXEL TO DOSTARLIMAB + DOCETAXEL TO DOCETAXEL ALONE IN PARTICIPANTS WITH ADVANCED NONSMALL CELL LUNG CANCER WHO HAVE PROGRESSED ON PRIOR ANTI PD (L)1 THERAPY AND CHEMOTHERAPY (COSTAR LUNG) — TERMINATED · PHASE3
• Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy — ACTIVE_NOT_RECRUITING · PHASE2
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer — COMPLETED · PHASE3
• A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Shared Decision Making on Radiation Dose for Lung Malignancies — ACTIVE_NOT_RECRUITING · NA
• A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, locally advanced, unresectable or metastatic PD-L1 selected non small cell lung cancer (GALAXIES LUNG 301) — TERMINATED · PHASE3
• IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC — COMPLETED · PHASE2
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL 1L) — OTHER · PHASE3
• NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer — ACTIVE_NOT_RECRUITING · NA
• Analysis of Circulating Tumor Markers in Blood - ALCINA 5 — NOT_YET_RECRUITING · NA
• Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer — WITHDRAWN · PHASE2
• Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) — TERMINATED · PHASE2
• Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors — OTHER
• A Clinical Evaluation of AI Solutions Developed in the CHAIMELEON Project for Cancer: Prostate, Lung, Breast, Colon and Rectum — COMPLETED
• Exploration of Risk Factors for Postoperative Cerebral Infarction in Lung Cancer Patients: a Retrospective Single-centre Study — ACTIVE_NOT_RECRUITING
• RaFIST: A Radiomics-Based Tool for Intratumoral Fibrosis Stratification in Non-Small Cell Lung Cancer — COMPLETED
• Quality of Life as a Predictor of OS and PFS in Patients With Lung Cancer — ACTIVE_NOT_RECRUITING
• SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type — NOT_YET_RECRUITING
• Comprehensive Demographics and Clinical Profile of NSCLC Patients — NOT_YET_RECRUITING
• Integrating Machine Learning for Prognostic Prediction in Stage I NSCLC by CT Images and Pathological Factors — COMPLETED
• CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors — OTHER · PHASE1
• The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial — NOT_YET_RECRUITING · NA
• Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC — NOT_YET_RECRUITING
• A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC — NOT_YET_RECRUITING · PHASE1
• Transbroncheal Novel PDT Peripheral Lung Tumor Ablation With 5-ALA — NOT_YET_RECRUITING · NA
• Application of Machine Learning Algorithms to Identify Optimal Candidates for Primary Tumor Resection in Patients with Metastatic Non-small Cell Neuroendocrine Tumors — COMPLETED
• Reinforced and Non-Reinforced Staple Lines in Fissureless Lobectomy — NOT_YET_RECRUITING · PHASE1
• Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer — COMPLETED · PHASE1
• Molecular Disease Characterization Initiative (MDCI) — TERMINATED · PHASE2

Refine this search